Circulatory Levels of Toxic Metals (Aluminum,Cadmium,Mercury,Lead) in Patients with Alzheimer’s Disease: A Quantitative Meta-Analysis and Systematic Review
Restricted accessResearch articleFirst published online February 6, 2018
Circulatory Levels of Toxic Metals (Aluminum,Cadmium,Mercury,Lead) in Patients with Alzheimer’s Disease: A Quantitative Meta-Analysis and Systematic Review
Environmental exposure to toxic metals has been postulated to play a role in the pathophysiological processes of Alzheimer’s disease (AD). However, the circulatory levels of toxic metals in AD patients are not consistent in previous studies.
Objective:
To systematically assess levels of toxic metals (aluminum, mercury, cadmium, lead) in the circulation (blood, serum/plasma) of AD patients and controls.
Methods:
PubMed, Web of Science, Science Direct, Cochrane Library, and the China National Knowledge Infrastructure (CNKI) were systematically searched to identify studies published up to January 1, 2017. Meta-analyses were performed using random-effects models and the pooled standardized mean difference (SMD) were reported with 95% confidence intervals (CI).
Results:
We identified 17, 7, 8, and 10 studies for aluminum, mercury, cadmium, and lead, respectively. Meta-analyses showed significantly elevated circulatory levels of aluminum (SMD = 1.08, 95% CI: 0.66, 1.50), mercury (SMD = 0.55, 95% CI, 0.15, 0.95), and cadmium (SMD = 0.62, 95% CI: 0.12, 1.11), whereas lower levels of lead (SMD = –0.23, 95% CI: –0.38, –0.07) in AD patients than in controls. Publication bias was only observed for aluminum studies, but the “trim and fill” analysis showed that the publication bias did not alter the direction of the effect. Sensitivity analyses showed no studies from the pooled analysis changed the results.
Conclusion:
Compared to controls, circulatory levels of aluminum, mercury, and cadmium are significantly higher but the levels of lead were reduced in AD patients. These findings suggest that elevated aluminum, mercury, and cadmium in the circulation, especially in serum may play a role in the progression of AD.
PozuetaJ, LefortR, ShelanskiML (2013) Synaptic changes in Alzheimer’s disease and its models. Neuroscience251, 51–65.
2.
PanayiAE, SpyrouNM, IversenBS, WhiteMA, PartP (2002) Determination of cadmium and zinc in Alzheimer’s brain tissue using inductively coupled plasma mass spectrometry. J Neurol Sci195, 1–10.
3.
YangQ, SongD, QingH (2017) Neural changes in Alzheimer’s disease from circuit to molecule: Perspective of optogenetics. Neurosci Biobehav Rev79, 110–118.
(2015) World Alzheimer Report 2015-The Global Impact of Dementia. Alzheimer’s Disease International, London.
6.
CoonKD, MyersAJ, CraigDW, WebsterJA, PearsonJV, LinceDH, ZismannVL, BeachTG, LeungD, BrydenL, HalperinRF, MarloweL, KaleemM, WalkerDG, RavidR, HewardCB, RogersJ, PapassotiropoulosA, ReimanEM, HardyJ, StephanDA (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease. J Clin Psychiatry68, 613–618.
7.
YegambaramM, ManivannanB, BeachTG, HaldenRU (2015) Role of environmental contaminants in the etiology of Alzheimer’s disease: A review. Curr Alzheimer Res12, 116–146.
8.
BakulskiKM, RozekLS, DolinoyDC, PaulsonHL, HuH (2012) Alzheimer’s disease and environmental exposure to lead: The epidemiologic evidence and potential role of epigenetics. Curr Alzheimer Res9, 563–573.
9.
González-DomínguezR (2017) Size fractionation of metal species from serum samples for studying element biodistribution in Alzheimer’s disease. Neuromethods124, 127–149.
10.
Chin-ChanM, Navarro-YepesJ, Quintanilla-VegaB (2015) Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci9, 124.
11.
KlatzoI, WisniewskiH, StreicherE (1965) Experimental production of neurofibrillary degeneration. I. Light microscopic observations. J Neuropathol Exp Neurol24, 187–199.
12.
MartynCN, BarkerDJ, OsmondC, HarrisEC, EdwardsonJA, LaceyRF (1989) Geographical relation between Alzheimer’s disease and aluminum in drinking water. Lancet1, 59–62.
13.
GiacoppoS, GaluppoM, CalabroRS, D’AleoG, MarraA, SessaE, BuaDG, PotortiAG, DugoG, BramantiP, MazzonE (2014) Heavy metals and neurodegenerative diseases: An observational study. Biol Trace Elem Res161, 151–160.
14.
OlivieriG, NovakovicM, SavaskanE, MeierF, BaysangG, BrockhausM, Muller-SpahnF (2002) The effects of beta-estradiol on SHSY5Y neuroblastoma cells during heavy metal induced oxidative stress, neurotoxicity and beta-amyloid secretion. Neuroscience113, 849–855.
15.
LaidlawMAS, PoropatAE, BallA, MielkeHW (2017) Exposure to lead in petrol and increased incidence of dementia. Lancet389, 2371–2372.
16.
GutiérrezF, ArcilaV, QuinteroK, ÁlvarezR, QueralesM (2014) Serum levels of aluminum in a group of patients with Alzheimer’s disease. Acta Bioquim Clin Latinoamericana48, 485–490.
17.
Gonzalez-DominguezR, Garcia-BarreraT, Gomez-ArizaJL (2014) Homeostasis of metals in the progression of Alzheimer’s disease. Biometals27, 539–549.
18.
TangJ, WuL, HuangH, FengJ, YuanY, ZhouY, HuangP, XuY, YuC (2013) Back propagation artificial neural network for community Alzheimer’s disease screening in China. Neural Regen Res8, 270–276.
19.
BaumL, ChanIH, CheungSK, GogginsWB, MokV, LamL, LeungV, HuiE, NgC, WooJ, ChiuHF, ZeeBC, ChengW, ChanMH, SzetoS, LuiV, TsohJ, BushAI, LamCW, KwokT (2010) Serum zinc is decreased in Alzheimer’s disease and serum arsenic correlates positively with cognitive ability. Biometals23, 173–179.
20.
SmorgonC, MariE, AttiAR, Dalla NoraE, ZamboniPF, CalzoniF, PassaroA, FellinR (2004) Trace elements and cognitive impairment: An elderly cohort study. Arch Gerontol Geriatr Suppl38, 393–402.
21.
RobertsNB, CloughA, BelliaJP, KimJY (1998) Increased absorption of aluminium from a normal dietary intake in dementia. J Inorg Biochem69, 171–176.
22.
ZapateroMD, Garcia de JalonA, PascualF, CalvoML, EscaneroJ, MarroA (1995) Serum aluminum levels in Alzheimer’s disease and other senile dementias. Biol Trace Elem Res47, 235–240.
23.
CorriganFM, CrichtonJS, Van RhijnAG, SkinnerER, WardNI (1992) Transferrin, cholesterol and aluminium in Alzheimer’s disease. Clin Chim Acta211, 121–123.
24.
BoccaB, ForteG, PetrucciF, PinoA, MarchioneF, BomboiG, SenofonteO, GiubileiF, AlimontiA (2005) Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer’s disease. Ann Ist Super Sanita41, 197–203.
25.
PagliaG, MiedicoO, CristofanoA, VitaleM, AngiolilloA, ChiaravalleAE, CorsoG, Di CostanzoA (2016) Distinctive pattern of serum elements during the progression of Alzheimer’s disease. Sci Rep6, 22769.
26.
AlimontiA, RistoriG, GiubileiF, StaziMA, PinoA, ViscontiA, BrescianiniS, Sepe MontiM, ForteG, StanzioneP, BoccaB, BomboiG, D’IppolitoC, AnnibaliV, SalvettiM, SancesarioG (2007) Serum chemical elements and oxidative status in Alzheimer’s disease, Parkinson disease and multiple sclerosis. Neurotoxicology28, 450–456.
27.
VirkSA, EslickGD (2015) Occupational exposure to aluminum and Alzheimer disease: A meta-analysis. J Occup Environ Med57, 893–896.
28.
VirkSA, EslickGD (2015) Aluminum levels in brain, serum, and cerebrospinal fluid are higher in Alzheimer’s disease cases than in controls: A series of meta-analyses. J Alzheimers Dis47, 629–638.
29.
WangZ, WeiX, YangJ, SuoJ, ChenJ, LiuX, ZhaoX (2016) Chronic exposure to aluminum and risk of Alzheimer’s disease: A meta-analysis. Neurosci Lett610, 200–206.
30.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
31.
American Psychological Association (1980) Diagnostic and statistical manual of mental disorders, 3rd edition. American Psychological Association, Washington, DC.
32.
KawaharaM, Kato-NegishiM (2011) Link between aluminum and the pathogenesis of Alzheimer’s disease: The integration of the aluminum and amyloid cascade hypotheses. Int J Alzheimers Dis2011, 276393.
33.
CrapperDR, KrishnanSS, DaltonAJ (1973) Brain aluminum distribution in Alzheimer’s disease and experimental neurofibrillary degeneration. Science180, 511–513.
34.
SalibE, HillierV (1996) A case-control study of Alzheimer’s disease and aluminium occupation. Br J Psychiatry168, 244–249.
35.
WaltonJR (2012) Aluminum disruption of calcium homeostasis and signal transduction resembles change that occurs in aging and Alzheimer’s disease. J Alzheimers Dis29, 255–273.
36.
NehruB, AnandP (2005) Oxidative damage following chronic aluminium exposure in adult and pup rat brains. J Trace Elem Med Biol19, 203–208.
37.
PraticoD, DelantyN (2000) Oxidative injury in diseases of the central nervous system: Focus on Alzheimer’s disease. Am J Med109, 577–585.
38.
TomljenovicL (2011) Aluminum and Alzheimer’s disease: After a century of controversy, is there a plausible link?J Alzheimers Dis23, 567–598.
39.
DragoD, CavaliereA, MascetraN, CiavardelliD, di IlioC, ZattaP, SensiSL (2008) Aluminum modulates effects of beta amyloid(1-42) on neuronal calcium homeostasis and mitochondria functioning and is altered in a triple transgenic mouse model of Alzheimer’s disease. Rejuvenation Res11, 861–871.
40.
HeymanA, WilkinsonWE, StaffordJA, HelmsMJ, SigmonAH, WeinbergT (1984) Alzheimer’s disease: A study of epidemiological aspects. Ann Neurol15, 335–341.
41.
WisniewskiHM, WenGY (1992) Aluminium and Alzheimer’s disease. Ciba Found Symp169, 142–154; discussion 154-164.
42.
RondeauV, Jacqmin-GaddaH, CommengesD, HelmerC, DartiguesJF (2009) Aluminum and silica in drinking water and the risk of Alzheimer’s disease or cognitive decline: Findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol169, 489–496.
43.
MutterJ, NaumannJ, SadaghianiC, SchneiderR, WalachH (2004) Alzheimer disease: Mercury as pathogenetic factor and apolipoprotein E as a moderator. Neuro Endocrinol Lett25, 331–339.
44.
BonackerD, StoiberT, WangM, BohmKJ, ProtsI, UngerE, ThierR, BoltHM, DegenGH (2004) Genotoxicity of inorganic mercury salts based on disturbed microtubule function. Arch Toxicol78, 575–583.
45.
BellingerFP, HeQP, BellingerMT, LinY, RamanAV, WhiteLR, BerryMJ (2008) Association of selenoprotein p with Alzheimer’s pathology in human cortex. J Alzheimers Dis15, 465–472.
46.
MutterJ, CurthA, NaumannJ, DethR, WalachH (2010) Does inorganic mercury play a role in Alzheimer’s disease? A systematic review and an integrated molecular mechanism. J Alzheimers Dis22, 357–374.
47.
TammC, DuckworthJ, HermansonO, CeccatelliS (2006) High susceptibility of neural stem cells to methylmercury toxicity: Effects on cell survival and neuronal differentiation. J Neurochem97, 69–78.
48.
MorrisMC, BrockmanJ, SchneiderJA, WangY, BennettDA, TangneyCC, van de RestO (2016) Association of seafood consumption, brain mercury level, and APOE epsilon4 status with brain neuropathology in older adults. JAMA315, 489–497.
49.
JainRB (2017) Factors affecting the variability in the observed levels of cadmium in blood and urine among former and current smokers aged 20-64 and ≥ 65years. Environ Sci Pollut Res Int24, 8837–8851.
50.
YanoK, HirosawaN, SakamotoY, KatayamaH, MoriguchiT (2003) 500 Aggregations of amyloid beta-proteins in the presence of metal ions. Toxicol Lett144, s134.
51.
St George-HyslopPH, PetitA (2005) Molecular biology and genetics of Alzheimer’s disease. C R Biol328, 119–130.
52.
JiangLF, YaoTM, ZhuZL, WangC, JiLN (2007) Impacts of Cd(II) on the conformation and self-aggregation of Alzheimer’s tau fragment corresponding to the third repeat of microtubule-binding domain. Biochim Biophys Acta1774, 1414–1421.
53.
MinJY, MinKB (2016) Blood cadmium levels and Alzheimer’s disease mortality risk in older US adults. Environ Health15, 69.
54.
PengQ, BakulskiKM, NanB, ParkSK (2017) Cadmium and Alzheimer’s disease mortality in U.S. adults: Updated evidence with a urinary biomarker and extended follow-up time. Environ Res157, 44–51.
55.
GerhardssonL, LundhT, MinthonL, LondosE (2008) Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord25, 508–515.
56.
CostaLG, FoxDA (1983) A selective decrease of cholinergic muscarinic receptors in the visual cortex of adult rats following developmental lead exposure. Brain Res276, 259–266.
57.
DuceJA, BushAI (2010) Biological metals and Alzheimer’s disease: Implications for therapeutics and diagnostics. Prog Neurobiol92, 1–18.
58.
CecilKM, BrubakerCJ, AdlerCM, DietrichKN, AltayeM, EgelhoffJC, WesselS, ElangovanI, HornungR, JarvisK, LanphearBP (2008) Decreased brain volume in adults with childhood lead exposure. PLoS Med5, e112.
59.
LiuJ, LiuX, WangW, McCauleyL, Pinto-MartinJ, WangY, LiL, YanC, RoganWJ (2014) Blood lead concentrations and children’s behavioral and emotional problems: A cohort study. JAMA Pediatr168, 737–745.
60.
VermaM, SchneiderJS (2017) Strain specific effects of low level lead exposure on associative learning and memory in rats. Neurotoxicology62, 186–191.
61.
HareDJ, FauxNG, RobertsBR, VolitakisI, MartinsRN, BushAI (2016) Lead and manganese levels in serum and erythrocytes in Alzheimer’s disease and mild cognitive impairment: Results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Metallomics8, 628–632.
62.
Gonzalez-DominguezR, Garcia-BarreraT, Gomez-ArizaJL (2014) Characterization of metal profiles in serum during the progression of Alzheimer’s disease. Metallomics6, 292–300.
63.
ParkJH, LeeDW, ParkKS, JoungH (2014) Serum trace metal levels in Alzheimer’s disease and normal control groups. Am J Alzheimers Dis Other Demen29, 76–83.
64.
LeeJY, KimJH, ChoiDW, LeeDW, ParkJH, YoonHJ, PyoHS, KwonHJ, ParkKS (2012) The association of heavy metal of blood and serum in the Alzheimer’s diseases. Toxicol Res28, 93–98.
65.
LiuK (2008) The study of the association between trace element and senile dementia/depressive disorder (Thesis). Shandong University Jinan, Shandong province, China.
66.
BoccaB, AlimontiA, BomboiG, GiubileiF, ForteG (2006) Alterations in the level of trace metals in Alzheimer’s disease. Trace Elem Electrolytes23, 270–276.
67.
TaylorGA, FerrierIN, McLoughlinIJ, FairbairnAF, McKeithIG, LettD, EdwardsonJA (1992) Gastrointestinal absorption of aluminium in Alzheimer’s disease: Response to aluminium citrate. Age Ageing21, 81–90.
68.
BasunH, ForssellLG, WetterbergL, WinbladB (1991) Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer’s disease. J Neural Transm Park Dis Dement Sect3, 231–258.
69.
BasunH, LindB, NordbergM, NordstromM, BjorkstenKS, WinbladB (1994) Cadmium in blood in Alzheimer’s disease and non-demented subjects: Results from a population-based study. Biometals7, 130–134.
70.
Kellett JTA, OramJJ, HalliwellB, GutteridgeJMC, WestRD (1986) Aluminosilicates and Alzheimer’s disease. Lancet1, 681–682.
71.
ShoreD, WyattRJ (1983) Aluminum and Alzheimer’s disease. Neurobiol Aging7, 525–532.
72.
JollyDH, PoitrinalP, MillartH, KarigerE, BlanchardF, ColleryP, ChoisyH (1993) Blood zinc, copper, magnesium, calcium, aluminum and manganese concentrations in patients, with or without Alzheimer type dementia. Trace Elem Med10, 192–195.
73.
FerrierIN, LeakeA, TaylorGA, McKeithIG, FairbairnAF, RobinsonCJ, FrancisRM, EdwardsonJA (1990) Reduced gastrointestinal absorption of calcium in dementia. Age Ageing19, 368–375.
